LEADER 03114nam  22005775  450 
001 9910734888203321
005 20260126101636.0
010   $a981-19-2615-8
024 7 $a10.1007/978-981-19-2615-0
035   $a(MiAaPQ)EBC7052066
035   $a(Au-PeEL)EBL7052066
035   $a(CKB)24286239500041
035   $a(PPN)263902439
035   $a(OCoLC)1337944361
035   $a(DE-He213)978-981-19-2615-0
035   $a(EXLCZ)9924286239500041
100   $a20220726d2022      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPharmacotherapy for Liver Cirrhosis and Its Complications /$fedited by Xingshun Qi, Yongping Yang
205   $a1st ed. 2022.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2022.
215   $a1 online resource (245 pages)
225 1 $aMedicine Series
311 08$aPrint version: Qi, Xingshun Pharmacotherapy for Liver Cirrhosis and Its Complications Singapore : Springer,c2022 9789811926143 
320   $aIncludes bibliographical references.
327   $aAnti-HBV drugs in liver cirrhosis -- Anti-HCV drugs in liver cirrhosis -- Anticoagulants in liver cirrhosis -- Antibiotics in liver cirrhosis -- Silymarin in liver cirrhosis -- Ursodeoxycholic acid in liver cirrhosis -- Emricasan in liver cirrhosis -- Non-selective beta blockers in liver cirrhosis -- Somatostatin and octreotide in liver cirrhosis -- Terlipressin in liver cirrhosis -- Diuretics in liver cirrhosis -- Statins in liver cirrhosis -- L-Ornithine L-Aspartate in liver cirrhosis -- Lactulose in liver cirrhosis.
330   $aThis book aims to provide an updated information on different types of major and emerging drugs for managing liver cirrhosis and its complications, including acute gastroesophageal variceal bleeding, ascites, hepatic encephalopathy, liver failure, acute kidney injury, and portal venous thrombosis. The chapters are organized by drug class, such as anti-HBV drugs, anti-HCV drugs, anticoagulants, and antibiotics, etc. The clinical efficacy, indication, and contra-indication of the various drug therapies are discussed using supportive reference material from authoritative sources and published clinical trials. It will be an invaluable reference for physicians who are treating patients with liver cirrhosis, especially those presenting with acute life-threatening complications.
410  0$aMedicine Series
606   $aInternal medicine
606   $aInternal Medicine
606   $aCirrosi hepątica$2thub
606   $aQuimioterąpia$2thub
608   $aLlibres electrņnics$2thub
615  0$aInternal medicine.
615 14$aInternal Medicine.
615  7$aCirrosi hepątica
615  7$aQuimioterąpia
676   $a616.3624
702   $aQi$b Xingshun
702   $aYang$b Yongping
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910734888203321
996   $aPharmacotherapy for liver cirrhosis and its complications$93403760
997   $aUNINA